No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Silexion Therapeutics Ltd. (SLXN) stock was $0.26 as of Oct 6, 2026, 4:00 PM EDT, down 1.20% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -99.3%
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform.
Biotechnology · Jerusalem, TA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-9.10
Revenue Est.
N/A
Last Quarter Results
EPS
$-5.17
vs Estimate
$-21.20
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SLXN | $110,112 | $0.26 | -1.20% | -99.31% | N/A | N/A | N/A |
| 2PBM | $95,475 | $5.02 | -1.18% | -73.54% | N/A | N/A | vs SLXN |
| 3PRFX | $70,884 | $0.88 | -0.46% | -87.06% | -74.50% | N/A | vs SLXN |
| 4AKAN | $61,172 | $1.89 | -1.05% | -96.82% | N/A | N/A | vs SLXN |
| 5ZCMD | $30,389 | $1.75 | -8.38% | -99.89% | -84.76% | N/A | vs SLXN |
| 6MNDR | $29,771 | $1.21 | -5.51% | -99.03% | N/A | N/A | vs SLXN |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$5.00
+1802.6% upside
Low
$5.00
Current
$0.26
High
$5.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-9.10 | $-9.10 | $-9.10 | 1 |
| Quarter ending Dec 2026 | $-7.10 | $-7.10 | $-7.10 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-48.45 | $-48.45 | $-48.45 | 1 |
| FY 2027 | $-20.25 | $-20.25 | $-20.25 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $0.00 |
| $0.00 |
| $0.00 |
| 0 |
